TUL wins China NMPA approval for new 0.3% sodium hyaluronate eye drops specification

• TUL received China NMPA clearance to market a new multi-dose sodium hyaluronate eye drops specification, 0.3% (5ml: 15mg).
• The product is used as artificial tears for dry-eye related corneal and conjunctival epithelial damage.
• The company said the added specification broadens its ophthalmic portfolio and supports competitiveness in China’s dry eye treatment market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260714-12244116), on July 14, 2026, and is solely responsible for the information contained therein.